Ren Jiaqiang, Jin Ping, Wang Ena, Liu Eric, Harlan David M, Li Xin, Stroncek David F
Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
J Transl Med. 2007 Jan 3;5:1. doi: 10.1186/1479-5876-5-1.
While insulin replacement remains the cornerstone treatment for type I diabetes mellitus (T1DM), the transplantation of pancreatic islets of Langerhans has the potential to become an important alternative. And yet, islet transplant therapy is limited by several factors, including far too few donor pancreases. Attempts to expand mature islets or to produce islets from stem cells are far from clinical application. The production and expansion of the insulin-producing cells within the islet (so called beta cells), or even creating cells that secrete insulin under appropriate physiological control, has proven difficult. The difficulty is explained, in part, because insulin synthesis and release is complex, unique, and not entirely characterized. Understanding beta-cell function at the molecular level will likely facilitate the development of techniques to manufacture beta-cells from stem cells. We will review islet transplantation, as well as the mechanisms underlying insulin transcription, translation and glucose stimulated insulin release.
虽然胰岛素替代仍然是I型糖尿病(T1DM)的基础治疗方法,但移植朗格汉斯胰岛有可能成为一种重要的替代方法。然而,胰岛移植治疗受到多种因素的限制,包括供体胰腺数量过少。试图扩增成熟胰岛或从干细胞产生胰岛的方法离临床应用还很远。在胰岛内产生和扩增产生胰岛素的细胞(即所谓的β细胞),甚至创造出在适当生理控制下分泌胰岛素的细胞,都已证明很困难。部分原因在于胰岛素的合成和释放复杂、独特且尚未完全明确。在分子水平上理解β细胞功能可能会促进从干细胞制造β细胞技术的发展。我们将回顾胰岛移植以及胰岛素转录、翻译和葡萄糖刺激胰岛素释放的潜在机制。